Curriculum Vitae

Wilhelmus (Wim) M.J. Vuist

115 John Kirk Ct
Campbell, CA 95008
Tel: (408) 796 7879
Email: wv61dd40@westpost.net
Education
2008 Attended the Mid-America Course in Toxicology, April 20-25, Kansas City, Ka
nsas, USA
1993 Post-Doc at Stanford Medical University, Department of Medicine/Oncology, L
ab of Dr. Ron Levy, Stanford, CA
1990 Ph.D. in Medicine, University of Amsterdam, The Netherlands Cancer Institut
e, Division of Immunology, Amsterdam, The Netherlands
Thesis: "Monoclonal antibodies and cytokines for the treatment of malignant lymp
homa."
Advisors: Dr. C. J. M. Melief and Dr. Ph. Rumke.
1985 MS in Biology, University of Utrecht, Utrecht, The Netherlands
Major: Tumor Immunology advisor: Dr. W. den Otter
Minors: Microbiology advisor: Dr. W. Hoekstra
Pharmacology advisor: Dr. D. deWied
Professional Experience
Consultant for Cephalon Inc., Redwood City, CA (2010-present)
Analyze literature information and write comprehensive recommendations for poten
tial antibody targets in oncology, inflammation and autoimmunity.
Consultant for Medarex, Milpitas, CA (2006-present)
-Design and evaluate the results of preclinical experiments with monoclonal anti
bodies specific for oncology targets in appropriate murine tumor model systems.
-Design and evaluate the results of preclinical toxicology experiments.
Senior Scientist, Discovery Research and Cell Biology, Medarex, Milpitas, CA (20
01-2004)
-Established and led the Tumor Immunology Group. This group generated preclinica
l data on 7 fully human monoclonal antibodies that unequivocally led to go (5/7)
and no-go (2/7) decisions for mAb development towards clinical trials.
-We generated mouse monoclonal antibodies against mouse CTLA-4 in a joint effort
with Dr. James Allison. One of these antibodies was used in syngeneic tumor mod
els and showed synergistic anti-tumor activity in combination with whole cell va
ccines or with anti-tumor mAbs.
- Project Leader on a project with an Australian company to develop fully human
mAbs against an oncology target. Developed the strategy and supervised a cross-
functional team of 10 resources in California to generate monoclonal antibodies
with the desired specificity.
Senior Scientist, GVAX Preclinical Research Group, Preclinical Biology and Immun
ology, Cell Genesys, Inc., Foster City, CA (1999-2001)
-Led this group to generate preclinical efficacy and safety data that validated
the use of the genomic GM-CSF gene for the production of GM-CSF producing whole
cell vaccines (GVAX).
-Key preclinical data was generated that showed a synergistic anti-tumor activit
y of combination treatments with GVAX and anti-CTLA-4 mAbs.
-GVAX preclinical research representative on the Cell Genesys ScientificAdvisory
Board. Fostered regular dialogues with Drs D Pardol and H Levitsky of John's H
opkins University, Baltimore, MD, Dr. R. Germain, NIH, Bethesda, MD, Dr B. Fox,
OHSU, Portland, OR and many other international scientists working on the develo
pment of tumor vaccines.
Senior Scientist, XenojectTM Research Project, Research and Development, SangSta
t Medical Corp., Menlo Park, CA (1997-1999)
- Led a research group to develop a novel drug platform i.e. XenojectTM.
-Discovered that anti-*Gal antibodies in human serum (mostly IgM) have extremely
low affinity for their antigen (*GAL) and were therefore not able to redirect t
hem to artificially generated *GAL containing proteins.
- Head of the Animal Facility. Supervised an animal technician, chaired the Inst
itutional Animal Use and Care Committee (IACUC), and wrote Standard Operating Pr
ocedures for the Animal Facility.
Assistant Professor at the University Maastricht, Divisions of Human Biology and
Biochemistry, Maastricht, The Netherlands (1995-1997)
- Supervised a research group which research was aimed at understanding the regu
lation of intracellular Ca2+ signaling in human blood platelets.
-Helped in the set-up of a microscope system that enabled us to study Ca2+ signa
ling at the level of single blood platelets.
-The research resulted in 6 publications in peer reviewed journals.
Research Fellow at the Academic Hospital Leiden, Division of Immunohematology/Bl
oodbank, Leiden, The Netherlands (1993-1995)
- Studied the mechanism of IvIg in inhibiting cell growth.
Fellow of the Dutch Cancer Society (1990-1993)
- Stanford University Hospital, Department of Medicine/Oncology,
Stanford, California, U.S.A. (Laboratory of Dr. R. Levy)
-The Netherlands Cancer Institute, Division of Immunology,
Amsterdam, The Netherlands (Laboratory of Dr. W. Martin Kast)
Ph.D. student at the Dutch Cancer Institute, Division of Immunology, Amsterdam t
he Netherlands.
-Elucidated the mechanism(s) of anti-cancer activity of mouse monoclonal antibod
ies in a xenograft model of human B cell lymphoma.
-Generated data that resulted in an industry standard paper on antibody dependen
t cellular cytotoxicity (ADCC). (Vuist, et.al, Cancer Immunol. Immunoth., 93, 16
3-170, 1993)
Grants and Honors Received
-Research Fellowship for two years from the Netherlands Cancer Society to perfor
m research in different international laboratories (1991)
-Travel Grant from The American Association of Cancer Research to present the re
sults of my post-doc research at their annual meeting in San Francisco (1994)
Memberships in Professional Organizations
American Association of Immunologists
American Association for the Advancement of Science

Bibliography

1. van Gorp, R.M., M.A. Feijge, W.M. Vuist, M.B. Rook, and J.W. Heemskerk. 2002.
Irregular spiking in free calcium concentration in single, human platelets. Reg
ulation by modulation of the inositol trisphosphate receptors. Eur J Biochem 269
:1543-1552.
2. Chiang, T.R., L. Fanget, R. Gregory, Y. Tang, D.L. Ardiet, L. Gao, C. Meschte
r, A.P. Kozikowski, R. Buelow, and W.M. Vuist. 2000. Anti-Gal antibodies in huma
ns and 1, 3alpha-galactosyltransferase knock-out mice. Transplantation 69:2593-2
600.
3. Keularts, I.M., R.M. van Gorp, M.A. Feijge, W.M. Vuist, and J.W. Heemskerk. 2
000. alpha(2A)-adrenergic receptor stimulation potentiates calcium release in pl
atelets by modulating cAMP levels. J Biol Chem 275:1763-1772.
4. Heemskerk, J.W., P. Siljander, W.M. Vuist, G. Breikers, C.P. Reutelingsperger
, M.J. Barnes, C.G. Knight, R. Lassila, and R.W. Farndale. 1999. Function of gly
coprotein VI and integrin alpha2beta1 in the procoagulant response of single, co
llagen-adherent platelets. Thromb Haemost 81:782-792.
5. Dekkers, D.W., P. Comfurius, W.M. Vuist, J.T. Billheimer, I. Dicker, H.J. Wei
ss, R.F. Zwaal, and E.M. Bevers. 1998. Impaired Ca2+-induced tyrosine phosphoryl
ation and defective lipid scrambling in erythrocytes from a patient with Scott s
yndrome: a study using an inhibitor for scramblase that mimics the defect in Sco
tt syndrome. Blood 91:2133-2138.
6. Vuist, W.M., M.A. Feijge, and J.W. Heemskerk. 1997. Kinetics of store-operate
d Ca2+ influx evoked by endomembrane Ca2+-ATPase inhibitors in human platelets.
Prostaglandins Leukot Essent Fatty Acids 57:447-450.
7. Heemskerk, J.W., W.M. Vuist, M.A. Feijge, C.P. Reutelingsperger, and T. Lindh
out. 1997. Collagen but not fibrinogen surfaces induce bleb formation, exposure
of phosphatidylserine, and procoagulant activity of adherent platelets: evidence
for regulation by protein tyrosine kinase-dependent Ca2+ responses. Blood 90:26
15-2625.
8. Vuist, W.M., I.N. Van Schaik, M. Van Lint, and A. Brand. 1997. The growth arr
esting effect of human immunoglobulin for intravenous use is mediated by antibod
ies recognizing membrane glycolipids. J Clin Immunol 17:301-310.
9. Brand, A., W.M. Vuist, I.N. Van Schaik, and M. Vermeulen. 1996. In vitro inve
stigation of immunoglobulin treatment mechanisms in autoimmune diseases. Clin Ex
p Rheumatol 14 Suppl 15:S27-30.
10. Vuist, W.M., R. Levy, and D.G. Maloney. 1994. Lymphoma regression induced by
monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig
signal transduction and is not prevented by tumor expression of high levels of
bcl-2 protein. Blood 83:899-906.
11. Vuist, W.M., M.J. Visseren, M. Otsen, K. Bos, F.A. Vyth-Dreese, C.G. Figdor,
C.J. Melief, and A. Hekman. 1993. Enhancement of the antibody-dependent cellula
r cytotoxicity of human peripheral blood lymphocytes with interleukin-2 and inte
rferon alpha. Cancer Immunol Immunother 36:163-170.
12. Hekman, A., A. Honselaar, W.M. Vuist, J.J. Sein, S. Rodenhuis, W.W. ten Bokk
el Huinink, R. Somers, P. Rumke, and C.J. Melief. 1991. Initial experience with
treatment of human B cell lymphoma with anti-CD19 monoclonal antibody. Cancer Im
munol Immunother 32:364-372.
13. Vuist, W.M., F. van Buitenen, A. Hekman, and C.J. Melief. 1990. Two distinct
mechanisms of antitumor activity mediated by the combination of interleukin 2 a
nd monoclonal antibodies. Cancer Res 50:5767-5772.
14. Vuist, W.M., F. v Buitenen, M.A. de Rie, A. Hekman, P. Rumke, and C.J. Melie
f. 1989. Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-p
an B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model. Can
cer Res 49:3783-3788.
15. Dullens, H.F., W. Vuist, M. Van der Maas, and W. Den Otter. 1986. The role o
f host lymphocytes and host macrophages in antitumor reactions after injection o
f sensitized lymphocytes and tumor target cells into naive mice. Cancer Immunol
Immunother 23:113-118.
16. Dullens, H.F., S. Schakenraad, A. Oostdijk, W. Vuist, M. Van der Maas, and W
. Den Otter. 1986. Specific tumoricidal activity of cytotoxic macrophages and cy
totoxic lymphocytes. Cancer Immunol Immunother 22:100-106.